Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 35, 26 April 2024
Open
Access | Article
Bioinformatics-based analysis of the prognostic value of CAF-related genes in lung squamous cell carcinoma
* Author to whom correspondence should be addressed.
Abstract
The survival rate for lung squamous cell carcinoma (LUSC) is significantly lower compared to other types of tumors, although some effective immunotherapies have been applied in the clinic. The prognosis of LUSC is largely dependent on the individual patient’s cancer assessment. Current clinical assessments based on clinical indicators and staging systems have limitations in accuracy. Therefore, prognostic prediction and assessment require precise and individualized assessment using genetic tools. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment have been reported to impact the survival of LUSC by expressing specific proteins regulated by CAF-related genes (CAFRGs). Building upon this, the study aimed to identify CAFRGs in the gene expression data of LUSC using weighted gene co-expression network analysis (WGCNA), and one-way Cox and lasso regression screened for prognostically relevant CAFRGs in LUSC, incorporating six independent CAFRGs related to prognosis, to establish a risk score model for LUSC patients, and to further investigate potential CAF biomarkers related to LUSC prognosis. The TCGA database served as the training set, while the external dataset GSE30219 from the GEO database was employed for validating the accuracy and reliability of the model. Univariate Cox and multivariate Cox regression analyses demonstrated the significance of this risk score as a crucial independent prognostic factor for LUSC. According to immune infiltration and differences in immunotherapy response, personalized treatment strategies suitable for people with different risk scores were derived. We posit that the findings from this study offer robust evidence regarding the association between CAFRGs and LUSC prognosis. This can aid in establishing a dependable prognostic risk model, facilitating more precise prognostic predictions to guide personalized treatment decisions.The survival rate for lung squamous cell carcinoma (LUSC) is significantly lower compared to other types of tumors, although some effective immunotherapies have been applied in the clinic. The prognosis of LUSC is largely dependent on the individual patient’s cancer assessment. Current clinical assessments based on clinical indicators and staging systems have limitations in accuracy. Therefore, prognostic prediction and assessment require precise and individualized assessment using genetic tools. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment have been reported to impact the survival of LUSC by expressing specific proteins regulated by CAF-related genes (CAFRGs). Building upon this, the study aimed to identify CAFRGs in the gene expression data of LUSC using weighted gene co-expression network analysis (WGCNA), and one-way Cox and lasso regression screened for prognostically relevant CAFRGs in LUSC, incorporating six independent CAFRGs related to prognosis, to establish a risk score model for LUSC patients, and to further investigate potential CAF biomarkers related to LUSC prognosis. The TCGA database served as the training set, while the external dataset GSE30219 from the GEO database was employed for validating the accuracy and reliability of the model. Univariate Cox and multivariate Cox regression analyses demonstrated the significance of this risk score as a crucial independent prognostic factor for LUSC. According to immune infiltration and differences in immunotherapy response, personalized treatment strategies suitable for people with different risk scores were derived. We posit that the findings from this study offer robust evidence regarding the association between CAFRGs and LUSC prognosis. This can aid in establishing a dependable prognostic risk model, facilitating more precise prognostic predictions to guide personalized treatment decisions.
Keywords
Squamous cell carcinoma of lung, CAF, Prognosis, Model of risk
References
1. Sung H, Ferlay J, Siegel R L, Laversanne M, Soerjomataram I, Jemal A; Bray F, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca-a Cancer Journal for Clinicians, 71: 209-249.
2. Siegel R L, Miller K D, Fuchs H E; Jemal A, 2022, Cancer statistics, 2022, Ca-a Cancer Journal for Clinicians, 72: 7-33.
3. Xu F, Lin H, He P, He L, Chen J, Lin L; Chen Y, 2020, A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma, Oncoimmunology, 9(1): 1731943.
4. Lai Y-H, Chen W-N, Hsu T-C, Lin C, Tsao Y; Wu S, 2020, Overall survival prediction of non-small cell lung cancer by integrating microarray and clinical data with deep learning, Scientific Reports, 10(1): 4679.
5. Lian S, Liu Z, Zhou Y, Guo J, Gong K; Wang T, 2020, The differential expression patterns and co-expression networks of paralogs as an indicator of the TNM stages of lung adenocarcinoma and squamous cell carcinoma, Genomics, 112: 4115-4124.
6. Zeng Z, Yang F, Wang Y, Zhao H, Wei F, Zhang P, Zhang X; Ren X, 2020, Significantly different immunoscores in lung adenocarcinoma and squamous cell carcinoma and a proposal for a new immune staging system, Oncoimmunology, 9(1):1828538
7. Hanahan D; Weinberg R A, 2011, Hallmarks of cancer: the next generation, Cell, 144: 646-674.
8. Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X; Shi S, 2021, Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives, Molecular Cancer, 20(1):131.
9. Li Y, Chen Y, Miao L, Wang Y, Yu M, Yan X, Zhao Q, Cai H, Xiao Y; Huang G., 2021, Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells, Cancer Letters, 497: 212-220.
10. Wu X, Zhou Z, Xu S, Liao C, Chen X, Li B, Peng J, Li D; Yang L, 2020, Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling, Cancer Letters, 478: 93-106.
11. De P, Aske J; Dey N, 2021, Cancer-associated fibroblast functions as a road-block in cancer therapy, Cancers, 13(20): 5246.
12. Slany A, Bileck A, Muqaku B; Gerner C, 2015, Targeting breast cancer-associated fibroblasts to improve anti-cancer therapy, Breast, 24: 532-538.
13. Shintani Y, Kimura T, Funaki S, Ose N, Kanou T; Fukui E, 2023, Therapeutic targeting of cancer-associated fibroblasts in the non-small cell lung cancer tumor microenvironment, Cancers, 15(2): 335.
14. Irvine A F, Waise S, Green E W, Stuart B; Thomas G J, 2021, Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis, Scientific Reports, 11(1): 3727.
15. Craddock K J, Ludkovski O, Sykes J, Shepherd F A; Tsao M-S, 2013, Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma, Journal of Thoracic Oncology, 8: 1371-1377.
16. Chen L, Chen M, Han Z, Jiang F, Xu C, Qin Y, Ding N, Liu Y, Zhang T, An Z; Guo C, 2018, Clinical significance of FAP-α on microvessel and lymphatic vessel density in lung squamous cell carcinoma, Journal of Clinical Pathology, 71: 721-728.
17. Zhang B, Horvath S, 2005, A general framework for weighted gene co-expression network analysis, Stat Appl Genet Mol Biol, 4: Article17.
18. Kalluri R, 2016, The biology and function of fibroblasts in cancer, Nature Reviews Cancer, 16: 582-598.
19. Ishii G, Ochiai A; Neri S, 2016, Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment, Advanced Drug Delivery Reviews, 99: 186-196.
20. Vaughan C A, Singh S, Subler M A, Windle J J, Inoue K, Fry E A, Pillappa R, Grossman S R, Windle B, Yeudall W A, Deb S P; Deb S, 2021, The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3, Nature Communications, 12(1):704.
21. Deng S, Lu X, Zhang Z, Meng R, Li M; Xia S, 2021, Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile, Journal of Cellular and Molecular Medicine, 25: 6652-6663.
22. Naderi A, 2018, SRARP and HSPB7 are epigenetically regulated gene pairs that function as tumor suppressors and predict clinical outcome in malignancies, Molecular Oncology, 12: 724-755.
23. Chen Z, Li P, Shen L; Jiang X, 2023, Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis, Oncology Reports, 50(5): 196.
24. Dong B; Wu Y, 2021, Epigenetic regulation and post-translational modifications of SNAI1 in cancer metastasis, International Journal of Molecular Sciences, 22(20): 11062.
25. Wang X, Liu R, Zhu W, Chu H, Yu H, Wei P, Wu X, Zhu H, Gao H, Liang J, Li G; Yang W, 2019, UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis, Nature, 571(7763): 127-131.
26. Gao L, Chen X, Wang Y, Zhang J, 2020, Up-Regulation of FSTL3, regulated by lncRNA DSCAM-AS1/miR-122-5p Axis, promotes proliferation and migration of non-small cell lung cancer cells, Oncotargets and Therapy, 13: 2725-2738.
27. Lei K, Liang R, Tan B, Li L, Lyu Y, Wang K, Wang W, Wang K, Hu X, Wu D, Lin H, Wang M, 2023, Effects of lipid metabolism-related genes PTGIS and HRASLS on phenotype, prognosis, and tumor immunity in lung squamous cell carcinoma, Oxid Med Cell Longev, 2023:6811625.
28. Labat-de-Hoz L, Rubio-Ramos A, Correas I; Alonso M A, 2023, The MAL family of proteins: normal function, expression in cancer, and potential use as cancer biomarkers, Cancers, 15(10): 2801.
29. Zhou M, Chen Y, Gu X, Wang C, 2022, A comprehensive bioinformatic analysis for identification of myeloid-associated differentiation marker as a potential negative prognostic biomarker in non-small-cell lung cancer, Pathology & Oncology Research, 28: 1610504.
30. Suzuki J, Aokage K, Neri S, Sakai T, Hashimoto H, Su Y, Yamazaki S, Nakamura H, Tane K, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Tsuboi M; Ishii G, 2021, Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma, Lung Cancer, 153: 1-10.
31. Zhang H, Zhu Z, Modrak S, 2022, Tissue-resident memory CD4 + T cells play a dominant role in the initiation of antitumor immunity, Journal of Immunology, 208: 2837-2846.
32. Xiang H, Ramil C P, Hai J, Zhang C, Wang H, Watkins A A, Afshar R, Georgiev P, Sze M A, Song X S, Curran P J, Cheng M, Miller J R., Sun D, Loboda A, Jia Y, Moy L Y, Chi A; Brandish P E, 2020, Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma, Cancer Immunology Research, 8: 436-450.
33. Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra H S, Mazieres J, Hermes B, Cicin I, Medgyasszay B, Rodriguez-Cid J, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B; Halmos B, 2020, A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407, Journal of Thoracic Oncology, 15: 1657-1669.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-395-1
- ISBN (Online)
- 978-1-83558-396-8
- Published Date
- 26 April 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/35/20240933
- Copyright
- 26 April 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited